Two BCG Shots Lowered Brain Amyloid; a Gut Toxin Aged 1,196 Brains [Best Read]
Plus lab-grown vessel patches revived ischemic pig hearts in four weeks, and dasatinib-plus-quercetin restored Klotho in aging kidneys.
In my work as a Silicon Valley based startup executive and longevity researcher, I track the gap between what the labs are publishing and what's actually worth adding to your protocol. Here's what stood out this week — with the numbers that matter.
Two BCG shots reshaped brain immunity and cut CSF amyloid in 12 pre-symptomatic adults [Communications Medicine]
Researchers ran two small, year-long open-label trials in adults 55 and older — 12 with no signs of Alzheimer's pathology and 11 who already had biomarker evidence of disease — giving each person two intradermal BCG shots a month apart. BCG, the century-old tuberculosis vaccine, is the best-studied trigger of "trained immunity," a durable reprogramming of the innate immune system. In the cerebrospinal fluid, BCG produced persistent, trained-immunity-like changes in immune cells that looked different from those in blood, hinting at brain-specific imprinting. In the participants without existing pathology, cerebrospinal-fluid amyloid-beta fell while blood amyloid-beta rose — the direction you would want if the brain were clearing the protein — with no unexpected safety signals. The catch: none of this appeared in people who already had Alzheimer's biomarkers, and 23 participants is far too few to change anything. For your protocol: it is too early to chase BCG for the brain, but this is the strongest human hint yet that immune "training" reaches the central nervous system, and it makes the early, pre-symptomatic window the one that matters.
A gut bacterial byproduct tracked worse brain aging across 1,196 adults [Nature Communications]
This one is a caution, not a supplement to add. Imidazole propionate (ImP) is a metabolite that certain gut bacteria pump out — more of it when diet and metabolism skew toward insulin resistance — and it was already linked to atherosclerosis. In a cohort of 1,196 cognitively healthy adults, higher blood ImP tracked with lower cognitive scores and worse dementia biomarkers, both at baseline and over time. A genome-wide analysis then pinned a chromosome-12 locus to both ImP levels and Alzheimer's risk, pointing to cause rather than coincidence, and in mice chronic ImP degraded the blood-brain barrier and drove tau tangles. The damage ran through the enzyme GSK-3-beta, and blocking it stopped the effect. For your protocol: this is a concrete reason to take gut health and metabolic control seriously — the same fiber-rich, insulin-sensitizing habits that lower ImP are levers you already control.
Lab-grown vessel patches lifted heart function in ischemic pigs within four weeks [The Scientist]
Surgeons can bypass a clogged coronary artery, but there is no standard fix for the tiny microvessels that actually feed heart muscle — and losing capillary density is a hallmark of aging throughout the body. A Stanford team built "vascular organoids" from endothelial progenitor cells drawn from human blood plus smooth-muscle cells derived from bone-marrow stem cells, then layered patches of them onto the hearts of pigs with ischemic heart disease. Over four weeks, treated pigs had better heart function than untreated animals, and their slide toward heart failure was blunted. The patches survived for weeks, raised microvessel density and maturity, and individual cells migrated down into deeper layers of the heart. Pigs are a far closer stand-in for the human heart than mice, which makes this more than a dish result. For your protocol: nothing to do yet, but capillary regeneration is a frontier worth watching — and a reminder that Zone 2 cardio, which grows your own capillaries, is the version available today.
Eight months of dasatinib-plus-quercetin restored Klotho and reversed kidney aging in mice [npj Regenerative Medicine]
Dasatinib (a generic leukemia drug) plus quercetin (a flavonol sold in any supplement aisle) is the original senolytic "hit-and-run" cocktail, and a new multi-omics study followed it long-term in the kidney. Starting at 12 months of age, mice received the D+Q combo by mouth every two weeks for eight months. Treated kidneys showed fewer senescence markers (p16, p21, SA-beta-gal), restored levels of the anti-aging protein Klotho, and less fibrosis and inflammation; single-cell sequencing showed transcriptional aging reversed across multiple kidney cell types. The mechanism traced back to reactivated PPAR-alpha signaling and better fat handling. Two caveats matter: this is mice, not people, and human D+Q trials remain small — and a recent controversy over how many senolytic studies measured the wrong p16 protein means even the biomarker wins deserve a skeptical read. For your protocol: D+Q is real and cheap, but optimal human dosing is still unproven, so treat any personal use as an experiment of one, not a settled protocol.
Brain-waste drainage was already failing in 18 adults with a pre-Parkinson's sleep disorder [npj Parkinson's Disease]
Your brain flushes metabolic waste — including the misfolded proteins behind neurodegeneration — largely during sleep, through the glymphatic system. Researchers used MRI to compare 18 people with isolated REM-sleep behavior disorder (iRBD), a condition that often precedes Parkinson's by years, against 20 healthy young and 18 older controls. The iRBD group had enlarged cerebrospinal-fluid and perivascular-space volumes without the matching drainage capacity seen in normal aging — a signature of fluid backing up rather than clearing. That stasis points to impaired filtration and weaker glymphatic clearance well before any movement symptoms appear. It is a small imaging study, but it reframes sluggish brain-waste drainage as an early, measurable event rather than a late consequence. For your protocol: protect deep sleep, when glymphatic clearance peaks, and treat REM-sleep behavior disorder (physically acting out dreams) as a signal worth raising with a clinician rather than ignoring.